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Abstract
Background: Lung cancer represents the most frequent cause of death for cancer. In non-small cell lung cancer
(NSCLC), which accounts for the vast majority of this disease, only early detection and treatment, when possible,
may significantly affect patient’s prognosis. An important role in NSCLC malignancy is attributed to the signal
transduction pathways involving PI3Kinase, with consequent activation of the AKT family factors. The serum and
glucocorticoid kinase (SGK) factors, which share high structural and functional homologies with the AKT factors, are
a family of ubiquitously expressed serine/threonine kinases under the control of cellular stress and hormones. SGK1
is the most represented SGK member.
Methods: By means of immunohistochemistry and quantitative real-time PCR, we determined SGK1 protein and
mRNA expression in a cohort of 66 formalin-fixed, paraffin-embedded NSCLC surgical samples. All samples
belonged to patients with a well-documented clinical history.
Results: mRNA expression was significantly higher in squamous cell carcinomas, and correlated with several clinical
prognostic indicators, being elevated in high-grade tumors and in tumors with bigger size and worse clinical stage.
No correlation was found between SGK1 protein expression and these clinical parameters.
Conclusions: This explorative analysis of SGK1 expression in NSCLC samples highlights the potential role of this
factor in NSCLC patients’ prognosis. Moreover, the higher expression in the squamous cell carcinoma subtype
opens new therapeutic possibilities in this NSCLC subtype by designing specific kinase inhibitors.
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Background
Lung cancer represents the foremost cause of cancer
death, at least in Western countries [1-3]. From a clini-
cal point of view, lung cancer is classified as “small cell
lung cancer” (SCLC) and “non-small cell lung cancer”
(NSCLC), the form by far most frequent (about 85% of
the total cases). NSCLCs are histopathologically subdi-
vided into adenocarcinoma, squamous cell carcinoma
and large cell carcinoma [1]. Recently, this NSCLC
subclassification has been shown to reflect also specific
epidemiological as well as biological behaviors, which
can be epitomized in a higher incidence in never-smo-
kers and in women of the adenocarcinomatous subtype
[4-7] and in its higher sensitivity to EGFR tyrosine
kinase inhibitors [8].
In NSCLC, a major role is attributed to the mem-
brane-bound tyrosine kinase receptors, mainly EGFR,
which in their active, phosphorylated form generate a
cascade of biological effects which strongly favor several
biological processes, as cell proliferation, neo-angiogen-
esis and invasive capability [9]. Interestingly, also insulin
and insulin receptor have been recently involved in lung
epithelial cells transformation [10,11]. A pivotal step of
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activation of the phosphoinositide-3-kinase (PI3Kinase)
pathway, which allows the convergence of several signals
in activating the AKT family of serine/threonine kinases,
thus stimulating cell growth, mitosis, survival and energy
metabolism [12-14]. The serum and glucocorticoid
kinase (SGK) family of serine/threonine kinases share
many structural and functional similarities with the
AKT family, since the metabolic pathways over which
both families exert their activity are extremely similar
[15]. SGK family is composed of three members, SGK1,
SGK2 and SGK3, coded by three different genes, which
are in turn subdivided into different splicing variants
[16]. SGK1, the most represented member of the SGK
family, is ubiquitously expressed and is under the con-
trol of cellular stress (including cell shrinkage) and hor-
mones (including gluco-and mineral-corticoids). All
isoforms are activated by insulin and other growth fac-
tors [15].
SGKs are involved in numerous pathophysiological
functions, and, among these, also neoplastic growth,
where SGK factors show often enhanced activity, influ-
encing several control mechanisms as cell growth and
proliferation [15], cell survival [17,18], cell migration
and invasion [19,20].
Recently, our group described the role of insulin and
insulin receptor in the early carcinogenic steps of some
NSCLCs [11]. Here we used quantitative real-time PCR
(qPCR) and immunohistochemistry (IHC) to determine
respectively mRNA and protein expression of SGK1
(total and phosphorylated/activated), the most repre-
sented family member, in archival NSCLC samples from
patients with a well-documented clinical history. This is
a retrospective study aiming at characterizing the role of
SGK1 in NSCLC onset and progression, and in setting
the ground for the possible use of SGK1 as a prognostic
factor or therapeutic target.
Methods
Patients
Tissues from 66 NSCLC surgical specimens (35 adeno-
carcinomas, 25 squamous cell carcinomas, plus 6 speci-
mens classified as “other”, which are 1 adenosquamous
carcinoma, 4 undifferentiated carcinomas and 1 large
cell carcinoma) were evaluated. All the patients were
diagnosed and treated at the Regina Elena Cancer Insti-
tute, Rome, Italy. Patients underwent international stan-
dard radio- and/or chemotherapeutic protocols. Clinical
data (patient history, diagnosis, staging and survival)
were obtained from the National Cancer Institute
“Regina Elena” databases. Survival data were integrated
by periodic interviews with patients and/or their rela-
tives. Samples were collected according to institutional
ethical guidelines. Written informed consent was
obtained from the patients for publication of this case
report and accompanying images. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
RNA extraction and Quantitative gene expression analysis
in NSCLC archival samples
Total RNA extraction from formalin-fixed, paraffin-
embedded (FFPE) NSCLC specimens was done essen-
tially according to the method described in previous
papers [21,22], using modifications concerning slice
thickness (7.5 μm instead of 10 μm) and optimizing the
time for proteinase digestion (5 h). Total RNA extracted
was examined and quantified using the 2100 bioanalizer
(Agilent, Santa Clara, CA). For qPCR reaction, the 7900
HT thermal cycler (Applied Biosystems, Branchburg,
NJ) apparatus was employed, as described previously
[11], using the sequence specific primer pairs described
in Table 1 [specific for SGK1 (all four isoforms), for
each of the four isoforms and for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), a qualitative and
quantitative transcripts control].
Histological examination and IHC
The histological diagnosis was re-evaluated in 2 μm
FFPE sections after routine laboratory haematoxylin/
eosin staining.
IHC analysis was done as described [11], omitting the
antigen retrieval step, and using a primary monoclonal
antibody for SGK1 (sc-28338, Santa Cruz Biotechnology,
Inc. Santa Cruz, CA), applied overnight (O.N.) at 4°C at
a dilution of 1:300. Phospho-SGK1 (pSGK1 Ser422) was
Table 1 Sequences of the primers used for qPCR of transcripts coding for SGK1 (all four isoforms), for each of the four
isoforms and for glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Gene Symbol Accession Number Sense Primer Antisense Primer
SGK1 (all 4 isoforms) N/A AGGGCAGTTTTGGAAAGGTT CTGTAAAACTTTGACTGCATAGAACA
SGK1 (isoform 1) NM_005627.3 GGCACCCTCACTTACTCCAG GGCAATCTTCTGAATAAAGTCGTT
SGK1 (isoform 2) NM_001143676.1 CGGTGGAAAATGGTAAACAAA CTTGATCCACCTTCGTACCC
SGK1 (isoform 3) NM_001143677.1 GAAGCTATAAAACCCCCTTTGAA GGCAATCTTCTGAATAAAGTCGTT
SGK1 (isoform 4) NM_001143678.1 CTTCCTGCTGAGCGGACT GGCAATCTTCTGAATAAAGTCGTT
GAPDH NM_002046 AGCCACATCGCTCAGACA GCCCAATACGACCAAATCC
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16745, Santa Cruz Biotechnology) applied for 2 h at 4°C
at a dilution of 1:100). For both antibodies, optimal
working dilution was defined on the basis of titration
experiments. The secondary antibody solution and
streptavidin-biotin, both contained in the QP900-9L kit
(BioGenex, San Ramon, CA.), were applied according to
the manufacturer’s instructions. Finally, 3-amino-9-
ethylcarbazide (AEC substrate kit, ScyTek, Logan, UT)
was used as chromogen. Mayer’s haematoxylin was used
for the nuclear counterstaining. Negative controls for
each tissue section were prepared by omitting the pri-
mary antibody.
Scoring and quantification of mRNA expression and
immunoreactivity
mRNA expression
Progression of the qPCR reaction, performed using the
primer pairs specified in Table 1, was monitored. All
the experiments were performed in quadruplicate.
Immunoreactivity
Two examiners (P.V. and M.G.P.) evaluated indepen-
dently the staining pattern of SGK1 and phospho-SGK1,
with subsequent discussion for the cases in which diver-
gent diagnoses were given. According to the amount of
staining, cases were classified in tertiles as follows: a)
negative/low; b) medium; c) high.
Statistical analysis
For quantitative variables, average values were deter-
mined, and the non-parametric Mann-Whitney U-test
was applied to evaluate statistical significance. All cate-
gorical variables were tested for statistical significance
by using Pearson’s c
2 test or Fisher’s exact test. Overall
survival (OS) and disease-free survival (DFS) curves
were done using the Kaplan-Meier method; the log-rank
(Mantel-Cox) test was used to compare survival times
between patient groups.
For all statistical tests, a two-tailed P-value < 0.05 was
considered as statistically significant.
Results
SGK1 and phospho-SGK1 protein detection in NSCLC
samples
SGK1 and phospho-SGK1 protein detection was done
b yI H Co nt i s s u es e c t i o n sf r o m6 6N S C L Cs p e c i m e n s
from patients with a well-documented clinical history.
The antibodies employed did not allow discriminating
among the SGK1 forms deriving from the four splicing
variants. Samples stained for SGK1 displayed a granular
cytoplasmic staining, considered specific due to its
absence in the negative controls. Staining appeared non-
homogeneous, with an intensity which was variable in
different areas of the sample. Samples stained for
phospho-SGK1 displayed a granular cytoplasmic staining
as well, with a range of intensity comparable to that of
SGK1. Figure 1 shows examples of negative and high
SGK1 and phospho-SGK1 staining in NSCLC samples.
According to staining intensity, samples were subdivided
into tertiles, consistent with the scoring given by two
pathologists, with null/low, medium and high SGK1
expression. Statistical evaluation found no correlation
between SGK1 or phospho-SGK1 staining and the fol-
lowing clinical parameters: a) age at diagnosis; b) gen-
der; c) smoking habit; d) histolopathogical subtype; e)
histopathological grade; f) tumor size; g) lymph node
stage; h) clinical tumor stage.
SGK1 mRNA detection in NSCLC samples
By means of the specific primers illustrated in Table 1,
we determined the mRNA amount of SGK1 either as
the sum of the four different splicing variants or as the
value specific for each single variant. In all cases,
GAPDH mRNA expression was used for an internal
check of the quality of the FFPE-extracted RNA and for
normalization. Total SGK1 mRNA expression data, and
the values for each splicing variant, were subdivided in
tertiles of 22 patients each. Data were challenged against
the clinical parameters described above. As far as it con-
cerns the evaluation of the expression of the sum of the
four SGK1 mRNA, statistically significant correlation
was found with:
a) histolopathogical subtype (P = 0.022), with the
highest expression in squamous cell carcinomas;
b) histopathological grade (P = 0.026), with the low-
est expression in low-grade tumors (G1) and the highest
expression in high-grade tumors (G3);
c) tumor size (P = 0.013), with lower expression in T1
and higher in T3-T4 tumors.
d) tumor stage (P = 0.028), where the highest expres-
sion was found in patients with worse clinical stage.
In this experimental set, no statistical significance was
found between SGK1 total mRNA expression and
patient’s gender, age, smoking history and lymph node
stage. All these data are summarized in Table 2. In addi-
tion, no correlation between SGK1 mRNA quantification
by qPCR and SGK1 protein (or phosphoprotein) expres-
sion by IHC was found.
When mRNA expression of each single SGK1 splicing
variant was considered, lower levels of statistical signifi-
cance were achieved, as reported below:
1. SGK1 variant 1: significant correlation with histolo-
pathogical subtype (P = 0.017), with the highest expres-
sion in squamous cell carcinomas; significant correlation
w i t ht h ee x p r e s s i o no ft h es u mo ft h ef o u rS G K 1s p l i -
cing variants (P =4 . 7×1 0
-6). Such a high significance
was due to the fact that this SGK1 form was by far the
most abundant splicing variant;
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pathogical subtype (p = 0.022), with the highest expres-
sion in squamous cell carcinomas; significant correlation
w i t ht h ee x p r e s s i o no ft h es u mo ft h ef o u rS G K 1s p l i -
cing variants (P = 0.001);
3. SGK1 variant 3: significant correlation only with the
expression of the sum of the four SGK1 splicing variants
(P = 0.003);
4. SGK1 variant 4: significant correlation only with the
expression of the sum of the four SGK1 splicing variants
(P = 0.008);
When survival data were analyzed (overall survival and
disease-free survival), Kaplan-Meier analysis did not
reach statistical significance in any cases. The best fit-
ting concerned the expression of SGK1 variant 3 and
disease-free survival (P = 0.083, non-significant), when
only the highest and lowest tertiles were taken into con-
sideration (Figure 2).
Discussion
The discovery and development of novel predictive tumor
biomarkers is a complicated process, and currently the
best choice for the identification of reliable markers
appears to be an intelligent compromise between the
results obtained from high-throughput technologies and
the so-called “hypothesis-driven” analyses, which are based
upon preliminary selections of factors whose expression is
to be estimated (biased approach) [23,24].
Following our previous results on insulin and activated
insulin receptor in NSCLC [11], we analyzed in this
High SGK1 staining
Negative phospho-SGK1 staining High phospho-SGK1 staining
Negative SGK1 staining
Figure 1 Immunohistochemical staining for SGK1 and phospho-SGK1. Representative samples showing negative and high SGK1 staining
(sum of all variants) and negative and high phospho-SGK1 in NSCLC. Original magnification = x20.
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phosphoprotein and mRNA expression in 66 NSCLC
FFPE surgical samples. The data of SGK1 expression
showing the best statistical fitting with patients’ clinical
parameters spring from the mRNA analysis rather than
IHC determinations. The most interesting data belong
to the set concerning the determination of the mRNA
expression of the sum of the four SGK1 splicing var-
iants. Each single splicing variant, when analyzed alone,
generated less statistically significant data. From these
results, we can assume that the biological role of these
different splicing variants goes largely in the same direc-
tion, at least in this experimental setting. Essentially, our
results showed higher SGK1 transcription in tissue
samples from patients with worse clinical prognostic
indicators, as, for example, histopathological grading.
Among all NSCLC cases, the squamous cell subtype
exhibited the highest SGK1 mRNA expression.
Considering SGK1 a factor strongly related to cellular
stress, it is not surprising that the highest expression
was found in high-grade tumors, because these are
usually characterized by higher rates of energy metabo-
lism, which expose them to relative hypo-oxygenation
and, paradoxically, to higher oxidative stress due to the
Warburg effect [25-28].
A direct correlation between SGK1 protein determina-
tion by IHC and tumor malignancy was not found. A
possible explanation comes from the notion that the
Table 2 Evaluation of SGK1 (all variants) mRNA expression in NSCLC samples by qPCR: correlation with
clinico-pathological parameters.
Null/low SGK1
expression
n=2 2
Medium SGK1
expression
n=2 2
High SGK1
expression
n=2 2
P-value
Patient age (years)
§ 69.1 ± 1.6 66.3 ± 2.4 65.2 ± 1.8 0.386
(NS)
Gender Male 11 13 15 0.471
(NS)
Female 11 9 7
Smoking habit Smokers 10 12 11 0.834
(NS)
Non-smokers 12 10 11
Histopathological
Subtype
Adenocarcinoma 15 12 8 0.022
Squamous cell
carcinoma
31 0 1 2
Other 4 0 2
Histopathological Grade G1 5 0 1 0.026
G2 8 15 9
G3 9 7 12
Tumor Size T1 9 2 6 0.013
T 2 12 15 10
T3 1 2 6
T4 0 3 0
Lymph Node Stage N 0 18 14 16 0.315
(NS)
N1 0 4 2
N2 3 3 4
N/A 1 1 0
Tumor Stage Stage I a 10 2 5 0.028
Stage I b 7 10 6
Stage II a 1 0 0
Stage II b 1 2 6
Stage III a 3 4 5
Stage III b 0 3 0
§ Average values; in bold and underlined = statistically significant results; N.S. = non-significant.
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ent, being essentially related to the presence or absence
of the “ER-motif” in the N-terminal region of the pro-
tein, a 6-amino acid sequence responsible for the bind-
ing to the endoplasmic reticulum (ER). The ER-motif,
when present, imposes a selective localization of the
SGK1 molecule on the ER, thus inducing its rapid
degradation via the ubiquitin pathway. For this reason,
SGK1 variants which possess the ER motif have a half-
life by far shorter than the other variants. Indeed, biolo-
gical activity of SGK1 variants provided of ER motif is
mainly regulated via a synthesis/degradation equilibrium
[29], while, for the other variants, regulation is mainly
due to post-translational modifications (phosphoryla-
tion/dephosphorylation) [15].
In this context, it is worth of note that the identifica-
tion of high SGK1 mRNA expression mainly in the
squamous cell subtype of NSCLC may pave the way for
specific targeted therapies in this NSCLC subtype.
Indeed, currently squamous cell carcinoma appears
neglected as far as targeted molecular therapies are con-
sidered, being most of these selective molecules
employed essentially for the adenocarcinoma subtype. If
the role of SGK1 as a specific molecular marker for
squamous cell carcinoma will be further validated, an
inhibitor of SGK1 kinase activity would be highly appre-
ciated in this NSCLC specific phenotype. Indeed, inhibi-
tors of the AKT family of serine/threonine kinases,
structurally and functionally closely related to the SGK
factors, have been already described, and their use in
clinical trials is underway [30-32].
It seems clear, however, that our knowledge on the
role of the SGK family factors in neoplastic diseases is
at a very early stage and that further studies are there-
fore necessary to indicate the most appropriate use of
the determination of these kinases in prognostic/predic-
tive evaluation of NSCLC patients as well as the possibi-
lity to consider them as a druggable target for specific
small molecule inhibitors.
Conclusions
This work is an explorative study on the role of SGK1,
the most represented member of the SGK family of ser-
ine/threonine kinases, in NSCLC. The notions derived
from our cohort of patients confirm the “oncogenic”
role of SGK1, where higher mRNA expression appears
related to patients with worse prognostic indicators.
Moreover, the significantly higher SGK1 expression in
the squamous cell subtype of NSCLC could indicate this
factor as central in establishing prognostic/predictive
parameters as well as in enforcing the design of SGK
serine/threonine kinase inhibitors to be employed in the
management of patients with squamous cell lung cancer.
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Figure 2 Disease-Free survival of NSCLC patients with high or low SGK1 variant 3 mRNA expression. Kaplan-Meier plot representing the
disease-free survival of NSCLC patients belonging to the high or low tertile for SGK1 variant 3 mRNA expression. In spite of a discernible trend
of better survival for NSCLC patients belonging to the low tertile for SGK1 variant 3 mRNA expression, when compared to the high tertile, with a
median value of 37 and 22 mo., respectively, these data are statistically non-significant (P-values = 0.083).
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